CHASKA, Minn., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 44th Annual J.P. Morgan Healthcare Conference. The conference will take place January 12-15, 2026, in San Francisco, California. Details regarding Lifecore’s participation are as follows: 44th Annual J.P. Morgan Healthcare ConferenceDetails: Lifecore management, includi ...

CHASKA, Minn., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 44th Annual J.P. Morgan Healthcare Conference. The conference will take place January 12-15, 2026, in San Francisco, California. Details regarding Lifecore’s participation are as follows: 44th Annual J.P. Morgan Healthcare ConferenceDetails: Lifecore management, includi ...

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of Lifecore Biomedical, Inc. (NASDAQ: LFCR) towards shareholders [1] Group 1: Legal Actions and Shareholder Rights - Long-term shareholders of Lifecore may seek corporate governance reforms, return of funds, court-approved financial incentives, or other benefits [2] - The firm operates on a contingent fee basis, meaning shareholders would not incur out-of-pocket legal fees [2] Group 2: Importance of Shareholder Participation - Shareholder involvement is crucial for improving company policies, practices, and oversight, which can lead to enhanced shareholder value [3] Group 3: Firm's Background and Achievements - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having recovered millions for defrauded investors [4]

Lifecore Biomedical FY Conference Summary Company Overview - Lifecore Biomedical has transitioned from a food conglomerate to a standalone Contract Development and Manufacturing Organization (CDMO) [3][4] - The company specializes in sterile injectables, which is the fastest-growing segment of the CDMO market, with a growth rate of approximately 10% [3] Key Points Transition and Leadership - The leadership team has been completely revamped, bringing in significant experience with nearly 150 years combined in the CDMO and pharmaceutical industry [8] - The company has improved its cash flow, investor relations, and media visibility, increasing the number of covering research analysts from two to five [5][6] Financial Performance and Projections - Lifecore reported $130 million in revenue and $20 million in EBITDA last year [25] - For the current stub period, the guidance is $74-$76 million in revenue and $12-$14 million in EBITDA [25] - The company aims for a low double-digit compound annual growth rate (CAGR) over the next three to four years, targeting a 12% CAGR and expanding EBITDA margins from 15% to 25% [26][27] Market Position and Opportunities - Lifecore has a strong foundation in hyaluronic acid (HA), which is critical for its business and customer retention [16][18] - The company has a pipeline of 12 late-stage programs expected to launch between 2026 and 2029, with multiple potential launches each year [12][26] - Lifecore is positioned to benefit from the trend of onshoring and reshoring pharmaceuticals, which has been accelerated by recent geopolitical events [14][30] Capacity and Utilization - Lifecore has approximately $300 million in annual revenue-generating capacity, currently operating at 20% utilization [20][34] - The company has invested $90 million in capital expenditures over the past five years to prepare for future growth [19] Regulatory and Compliance - Lifecore has a clean regulatory track record, which is crucial for building customer trust in the CDMO space [32][33] - The company recently underwent a successful FDA audit with only minor observations [9] Strategic Initiatives - A new commercial strategy has been implemented, focusing on aggressive business development and marketing to maximize opportunities [10][11] - The company is also implementing an ERP system expected to go live in Q1 2026, which will enhance operational efficiency [6][47] Customer Relationships - Lifecore has established long-term relationships with customers, some lasting 20-40 years, particularly in the ophthalmic and orthopedic sectors [4][18] - The company has closed 14 new opportunities since the leadership change, with nine in the last 12 months [11] Capital Allocation and Future Investments - Lifecore ended the last quarter with $42.5 million in liquidity, including $18.9 million in cash [54] - Future capital expenditures are expected to be in the range of $7.5 million to $10 million annually, split between maintenance and growth [55] Conclusion - Lifecore Biomedical is positioned for predictable growth with a strong commercial foundation and a robust late-stage pipeline. The company is optimistic about its future, aiming to become a significant player in the CDMO market while improving healthcare outcomes [60]

Lifecore Biomedical Conference Call Summary Company Overview - Lifecore Biomedical is a sterile injectable Contract Development and Manufacturing Organization (CDMO) with a focus on high-value development pipelines and strong commercial partnerships [2][4] - The company has approximately 400 employees and is located in Chaska, Minnesota, celebrating its 60th anniversary in 2025 [3][4] - Lifecore operates under one quality management system across three sites, enhancing operational efficiency [5] Financial Performance - For fiscal year 2025, Lifecore reported approximately $129 million in revenue and $20 million in adjusted EBITDA, resulting in a 15% EBITDA margin [4][7] - The company has guided for fiscal 2026 revenue between $74-$76 million with adjusted EBITDA of $12-$14 million [8] - Lifecore has improved its liquidity position significantly, ending September 2025 with $42.5 million in liquidity, including $19 million in cash and $23.5 million available on its revolver [9] Market Dynamics - The global CDMO market is valued at approximately $120 billion, with the injectable market alone around $10 billion, growing at approximately 10% [10] - Lifecore is positioned to benefit from the regionalization of manufacturing in the U.S., a trend accelerated by the COVID-19 pandemic [10][11] - The company sees opportunities arising from the transition of manufacturing from Asia-Pacific and Europe to the U.S. [11] Growth Strategy - Lifecore aims for a 12% compound annual growth rate (CAGR) over the midterm, targeting revenue of approximately $178-$205 million within the next 36-42 months [14][15] - The company plans to improve adjusted EBITDA margins from 15% to over 25% through operational efficiencies and increased utilization of capacity [14][16] - Lifecore has a late-stage pipeline of 32 programs, with 12 classified as late-stage, representing a revenue potential of $150 million-$200 million [18][19] Capacity and Investment - Lifecore has invested over $90 million in capacity enhancements, including a state-of-the-art five-head isolator filler that has increased capacity by over 100% [11][12] - The company currently has $300 million in revenue-generating capacity, with minimal additional capital expenditures required to support midterm growth [25] Competitive Landscape - Lifecore differentiates itself through its technical expertise, quality management systems, and integrated model, which are seen as key competitive advantages [23] - The company has revamped its commercial strategy to adopt a more aggressive approach in acquiring new business, resulting in nine new business wins in the past two months [20] Key Takeaways - Lifecore Biomedical is positioned for durable revenue growth and margin expansion, with a strong leadership team capable of executing its aggressive growth strategy [22] - The company is viewed as an undervalued opportunity within the high-growth CDMO market [22]

Core Insights - Greenhaven Road Capital reported a third-quarter 2025 return of approximately -9%, resulting in year-to-date returns also at approximately -9% [1] - The fund's performance was negatively impacted by a lack of direct investment in AI, no overlap with major indices like the S&P 500 and Russell 2000, and insufficient holdings in small, high-growth, unprofitable companies that have benefited from the AI landscape [1] Company Focus: Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Lifecore Biomedical, Inc. is highlighted as a key stock, with a one-month return of 3.63% and a 52-week gain of 4.74% [2] - As of November 7, 2025, Lifecore Biomedical's stock closed at $6.85 per share, with a market capitalization of $256.645 million [2] - The investor letter expressed confidence in Lifecore Biomedical's intrinsic value, suggesting that the market has yet to recognize its true worth [3]

Core Insights - The fund experienced a return of approximately -9% during Q3, leading to a year-to-date return of approximately -9% [2] - The portfolio lacks direct exposure to AI, focusing instead on companies that are integrating AI into their operations, which has affected short-term performance [3][5] - The investment strategy emphasizes long-term growth potential and durable competitive advantages rather than short-term market trends [5][8] Portfolio Analysis - The top five holdings include PAR Technologies, Cellebrite, KKR, LifeCore, and Burford, all of which have faced declines in share price year-to-date [7][32] - LifeCore's share price dropped over 10% following a shelf offering announcement, despite positive business developments [12][15] - Cellebrite's valuation has been impacted by a general decline in software multiples, with a 26% drop in Enterprise Value to Next 12 Months Revenue for medium growth companies [17][18] Company-Specific Developments - LifeCore is expected to ramp up revenues significantly by 2026, driven by new customer wins and favorable regulatory changes [13][15] - Cellebrite is positioned to benefit from AI advancements, with plans to release investigative AI tools in January 2026 [20][22] - KKR's diversified asset management approach remains robust, with significant growth in Fee Related Earnings and a focus on expanding its investor base [25][31] Market Trends and Challenges - The current market environment has led to a compression of software multiples, affecting companies like Cellebrite and PAR Technologies [18][46] - Concerns regarding traditional private equity and private credit have emerged, but KKR's diversified model mitigates some of these risks [24][30] - The investment landscape is characterized by volatility, with a disconnect between share prices and underlying business progress [10][42] Future Outlook - The fund's strategy focuses on long-term value realization, with expectations that current market conditions will eventually improve for the companies held [9][43] - There is potential for significant growth in companies like Hagerty and Kingsway, driven by strategic partnerships and management quality [33][35] - The outlook for PAR Technologies hinges on winning key contracts, which could substantially increase recurring revenue and growth rates [51][60]

Core Insights - Lifecore Biomedical reported a quarterly loss of $0.29 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.30, and an improvement from a loss of $0.53 per share a year ago, indicating an earnings surprise of +3.33% [1] - The company achieved revenues of $31.11 million for the quarter ended August 2025, exceeding the Zacks Consensus Estimate by 16.60%, and showing growth from $24.7 million in the same quarter last year [2] - Lifecore Biomedical has surpassed consensus EPS estimates two times over the last four quarters and topped consensus revenue estimates three times during the same period [2] Stock Performance - Lifecore Biomedical shares have declined approximately 8.9% since the beginning of the year, contrasting with the S&P 500's gain of 15.6% [3] - The future price movement of the stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [3][4] Earnings Outlook - The estimate revisions trend for Lifecore Biomedical was mixed ahead of the earnings release, leading to a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market in the near future [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Financial Data and Key Metrics Changes - Revenues for Q3 2025 were $31.1 million, a 26% increase compared to $24.7 million for the comparable prior period [15][16] - Adjusted EBITDA for Q3 2025 was $3.1 million, an increase of $4.9 million compared to a negative $1.8 million in the comparable prior period [18][19] - The company recorded a net loss of $10 million for Q3 2025, an improvement from a net loss of $16.2 million in the comparable prior period [18] Business Line Data and Key Metrics Changes - HA manufacturing revenues increased by $4.8 million due to increased demand from a customer [15][16] - CDMO revenues increased by $1.6 million, primarily from higher sales volumes, but were partially offset by lower development revenue [16] Market Data and Key Metrics Changes - The company is experiencing a buoy in its pipeline of commercial site transfer opportunities from regions such as Asia, Europe, and India, indicating a favorable market environment for CDMOs [31] Company Strategy and Development Direction - Lifecore is focused on growth with a revamped commercial strategy and a promising late-stage pipeline of 11 programs expected to launch between 2026 and 2029 [5][9] - The company aims to increase adjusted EBITDA margins through operational excellence and disciplined cost control, targeting a midterm goal of 25% [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future growth driven by a strong foundation in high-grade hyaluronic acid and a forecasted inflection point with their largest customer in 2027 [5][6] - The company is committed to improving its cost structure and productivity, with expectations of further efficiencies and productivity gains [12][13] Other Important Information - Lifecore has signed two new business wins during the third quarter and made substantial progress on additional projects [7][10] - The company expects revenue for the transition period from May 26 to December 31, 2025, to be approximately $74-$76 million [19][20] Q&A Session Summary Question: What would the missing month imply for Q4? - Estimated revenues for June were about $8.7 million, leading to Q4 revenue guidance of $34-$36 million, representing an 8% increase over the comparable prior year quarter [24][25] Question: Are there additional levers to pull on cost reductions? - There is potential for further reductions in SG&A expenses, with an estimated $1.5 million per quarter possible as legacy matters are resolved [26][27] Question: How are early conversations progressing regarding manufacturing capacity? - The regionalization of manufacturing is seen as a tailwind for CDMOs, with increased opportunities for commercial site transfers [31] Question: What is the expected timeline for the tech transfer agreement? - The commercial site transfer is expected to take approximately 24-30 months [35][36] Question: Will revenues be expected before the full transfer is complete? - The company anticipates being the sole manufacturer once fully qualified, with significant capacity expected to be consumed by this product [42]

Revenue and Profitability - Total revenues for the three months ended September 30, 2025, increased by 26% to $31,109,000 compared to $24,705,000 for the three months ended August 25, 2024[129]. - HA manufacturing revenues surged by 107% to $9,360,000, driven by increased demand from a customer due to supply chain initiatives[130]. - Gross profit rose by 45% to $7,791,000, with a gross profit margin of 25.0%, up from 21.8% in the prior year[129]. Operating Expenses and R&D - Operating expenses decreased by 36% to $10,858,000, primarily due to a $5,890,000 reduction in selling, general, and administrative expenses[132]. - R&D expenses slightly declined to $1,963,000, reflecting consistent product development activities[133]. Interest and Debt Management - Interest expense increased by 19% to $6,384,000 compared to $5,383,000 in the prior year[135]. - The company had $179.6 million in borrowings outstanding under the Term Loan Credit Facility at an effective annual interest rate of 20.9%[153]. - Interest paid-in-kind under the Term Loan Credit Facility for the three months ended September 30, 2025, was $4.4 million[153]. - The company repaid $2.5 million of borrowings under the Revolving Credit Facility in June 2025[154]. Cash Flow and Liquidity - As of September 30, 2025, the company had cash of $18.9 million and received $10.0 million from early payment of principal under its note receivable[140]. - The company had approximately $23.6 million available for borrowing under the Revolving Credit Facility, with a maximum committed amount of $40.0 million[141]. - Cash flow improved by $1.6 million in the three months ended September 30, 2025, primarily due to a $2.4 million improvement in operating cash flows[142]. - The company expects its existing cash and cash generated from operations to be sufficient to finance its current operational and capital requirements for at least the next twelve months[144]. Strategic Initiatives - The company plans to launch a new ERP system in Q1 2026 to enhance inventory control and financial management[120]. - Lifecore improved workforce productivity by over 20% in the past year through targeted initiatives[120]. - The company has guaranteed contractual minimum purchasing commitments with Alcon through 2031[113]. - A significant prepayment of $5,500,000 from Alcon will be settled starting January 2026 through monthly credit memos[113]. Preferred Stock and Dividends - As of September 30, 2025, there were $0.9 million of dividends in arrears on the Redeemable Convertible Preferred Stock, representing $12.50 per preferred share[147]. - The aggregate liquidation preference of the Redeemable Convertible Preferred Stock was $47.5 million as of September 30, 2025[148]. - The company is considering financing alternatives to fund the Series A liquidation preference, which may include equity financing or debt financing[149].